U.S. FDA approves first nasal spray for allergic reactions (2024)

Market Closed - Nasdaq Other stock markets 04:00:00 2024-08-09 pm EDT			5-day change	1st Jan Change
10.88 ^USD	+10.01%		+9.90%	+98.54%

Aug. 09	ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions	MT
Aug. 09	ARS Pharmaceuticals, Inc. Receives FDA Approval of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis	CI

Summary

Quotes

Charts

News

Company

Financials

Valuation

Consensus

Calendar

Sector

Latest news about ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions	Aug. 09	MT
ARS Pharmaceuticals, Inc. Receives FDA Approval of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis	Aug. 09	CI
FDA Approves ARS Pharma's Neffy Nasal Spray for Emergency Allergy Treatment	Aug. 09	DJ
U.S. FDA approves first nasal spray for allergic reactions	Aug. 09	RE
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 06	CI
Asahi Songwon Colors Appoints CFO	Jul. 28	MT
Asahi Songwon Colors Limited Announces Chief Financial Officer Changes	Jul. 27	CI
Raymond James Starts ARS Pharmaceuticals With Outperform Rating	Jul. 25	MT
Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	Jul. 11	MT
Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	Jul. 11	MT
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000E Value Index	Jun. 30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Value Index	Jun. 30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000 Value Index	Jun. 30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2500 Value Index	Jun. 30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Microcap Value Index	Jun. 30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion	Jun. 28	MT
EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen	Jun. 28	RE
ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)	Jun. 28	CI
Ars Pharmaceuticals Insider Sold Shares Worth $913,917, According to a Recent SEC Filing	Jun. 13	MT
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	Apr. 30	CI
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	Apr. 30	CI
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18	MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18	MT

Chart ARS Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Employees

Sector

Calendar

2024-11-06 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.88USD

Average target price

19.00USD

Spread / Average Target

+74.63%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Stock Market
Equities
SPRY Stock
News ARS Pharmaceuticals, Inc.
U.S. FDA approves first nasal spray for allergic reactions

Secure and Increase the Performance of your Investments with our Team of Experts at your Side Secure my Investments

"); for (var element in ICConf) { if (document.getElementById("zpp"+element)) { document.getElementById("zpp"+element).innerHTML = ""; } } InvestingChannelQueue.push(function() { ic_page = InvestingChannel.UAT.Run("5c5a75c3-8896-4592-98f8-dc06e6fdcc56"); }); } gaEvent('adspv', 'InvestingChannel_v2', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '116155892');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });